Hold Aurobindo Pharma; target of Rs 710: Sharekhan
Sharekhan recommended Hold rating on Aurobindo Pharma with a target price of Rs 710 in its research report dated August 08, 2019.
August 12, 2019 / 05:11 PM IST
Sharekhan's research report on Aurobindo Pharma
Q1 numbers were strong; new products, better product mix and operational efficiencies led to robust profitability. Gross debt reduced by ~ Rs 1,084 crore to Rs. 5883.2 crore; net debt fell by Rs. 915 crore to Rs. 4,094 crore. Regulatory hurdles at various plants would weigh on stock until successful resolution.
We maintain a Hold rating with an unchanged PT of Rs. 710. We expect company to report sales and profit CAGRs of 29% and 22%,
respectively, in the next two years.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.